Pubblicazioni

Nome Numero di download Versione Proprietario Ultima modifica Valutazione
Nome Numero di download Versione Proprietario Ultima modifica Valutazione
179 file scaricati 1.0 admin 08-01-2019 22:11
316 file scaricati 1.0 admin 24-09-2018 17:15
594 file scaricati 1.0 admin 24-09-2018 17:14
193 file scaricati 1.0 admin 24-09-2018 17:03
158 file scaricati 1.0 admin 24-09-2018 17:02
342 file scaricati 1.0 admin 25-07-2018 16:09
243 file scaricati 1.0 admin 16-07-2018 17:27
189 file scaricati 1.0 admin 22-02-2018 13:00
225 file scaricati 1.0 admin 22-02-2018 13:00

Pubblicazioni Vironet C

  • Bertoli A, Sorbo MC, Aragri M, Lenci I, Teti E, Polilli E, Di Maio VC, Gianserra L, Biliotti E, Masetti C, Magni CF, Babudieri S, Nicolini LA, Milana M, Cacciatore P, Sarmati L, Pellicelli A, Paolucci S, Craxì A, Morisco F, Palitti VP, Siciliano M, Coppola N, Iapadre N, Puoti M, Rizzardini G, Taliani G, Pasquazzi C, Andreoni M, Parruti G, Angelico M, Perno CF, Cento V, Ceccherini-Silberstein F1; HCV Virology Italian Resistance Network (VIRONET-C). Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy. Sci Rep. 2018 Jun 12;8(1):8988.
    https://www.ncbi.nlm.nih.gov/pubmed/29895871
  • Di Maio VC, Cento V, Aragri M, Paolucci S, Pollicino T, Coppola N, Bruzzone B, Ghisetti V, Zazzi M, Brunetto M, Bertoli A, Barbaliscia S, Galli S, Gennari W, Baldanti F, Raimondo G, Perno CF, Ceccherini-Silberstein F; HCV Virology Italian  Resistance Network (VIRONET-C). Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? J Hepatol. 2018 Mar;68(3):597-600. doi: 10.1016/j.jhep.2017.09.008. Epub 2017 Sep20. PubMed PMID: 28939133.
    https://www.ncbi.nlm.nih.gov/pubmed/28939133
  • Cento V, Aragri M, Teti E, Polilli E, Bertoli A, Foroghi L, Barbaliscia S, Di Maio VC, Pieri A, Pace Palitti V, Sarmati L, Parruti G, Andreoni M, Perno CF, Ceccherini-Silberstein F. Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study. J Antimicrob Chemother. 2017 Dec 1;72(12):3420-3424. doi: 10.1093/jac/dkx302. PubMed PMID: 28961921. https://www.ncbi.nlm.nih.gov/pubmed/28961921
  • Cento V, Barbaliscia S, Lenci I, Ruggiero T, Magni CF, Paolucci S, Babudieri S, Siciliano M, Pasquazzi C, Ciancio A, Perno CF, Ceccherini-Silberstein F; HCV retreatment team VIRONET-C study group. Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life. Clin Microbiol Infect. 2017 Oct;23(10):777.e1-777.e4. doi: 10.1016/j.cmi.2017.04.005. Epub 2017 Apr 12. PubMed PMID: 28412381.
    https://www.ncbi.nlm.nih.gov/pubmed/?term=ceccherini+silberstein+cento+lenci+optimal
  • Di Maio VC, Cento V, Lenci I, Aragri M, Rossi P, Barbaliscia S, Melis M, Verucchi G, Magni CF, Teti E, Bertoli A, Antonucci F, Bellocchi MC, Micheli V, Masetti C, Landonio S, Francioso S, Santopaolo F, Pellicelli AM, Calvaruso V, Gianserra L, Siciliano M, Romagnoli D, Cozzolongo R, Grieco A, Vecchiet J, Morisco F, Merli M, Brancaccio G, Di Biagio A, Loggi E, Mastroianni CM, Pace Palitti V, Tarquini P, Puoti M, Taliani G, Sarmati L, Picciotto A, Vullo V, Caporaso N, Paoloni M, Pasquazzi C, Rizzardini G, Parruti G, Craxì A, Babudieri S, Andreoni M, Angelico M, Perno CF, Ceccherini-Silberstein F; HCV Italian Resistance Network Study Group. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. Liver Int. 2017 Apr;37(4):514-528. doi: 10.1111/liv.13327. Epub 2017 Jan 20. PubMed PMID: 28105744.
    https://www.ncbi.nlm.nih.gov/pubmed/28105744
  • Di Maio VC, Cento V, Di Paolo D, Aragri M, De Leonardis F, Tontodonati M, Micheli V, Bellocchi MC, Antonucci FP, Bertoli A, Lenci I, Milana M, Gianserra L, Melis M, Di Biagio A, Sarrecchia C, Sarmati L, Landonio S, Francioso S, Lambiase L, Nicolini LA, Marenco S, Nosotti L, Giannelli V, Siciliano M, Romagnoli D, Pellicelli A, Vecchiet J, Magni CF, Babudieri S, Mura MS, Taliani G, Mastroianni C, Vespasiani-Gentilucci U, Romano M, Morisco F, Gasbarrini A, Vullo V, Bruno S, Baiguera C, Pasquazzi C, Tisone G, Picciotto A, Andreoni M, Parruti G, Rizzardini G, Angelico M, Perno CF, Ceccherini-Silberstein F; HCV Italian Resistance Network Study Group. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. J Antimicrob Chemother. 2016 Mar;71(3):739-50. doi: 10.1093/jac/dkv403. Epub 2015 Dec 17. PubMed PMID: 26679249.
    https://www.ncbi.nlm.nih.gov/pubmed/26679249

Altre pubblicazioni utili

2018

  • Asselah T, Bourgeois S, Pianko S, et al.: Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis. Liver Int 2018 Mar, 38:443–450.
    https://www.ncbi.nlm.nih.gov/pubmed/28756625
  • Calvaruso V, Cabibbo G, Cacciola I, et al.: Incidence of Hepatocellular Carcinoma in Patients with HCV-associated Cirrhosis Treated with Direct-Acting Antiviral Agents. Gastroenterology. 2018 Apr 12. pii: S0016-5085(18)30441-4.
    https://www.ncbi.nlm.nih.gov/pubmed/29655836
  • Calvaruso V, Ferraro D, Licata A, et al.: HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals. J Viral Hepat. 2018 Jan;25(1):72-79.
    https://www.ncbi.nlm.nih.gov/pubmed/28703895
  • Caudai C, Materazzi A, Saladini F, et al.: Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy. Clin Microbiol Infect. 2018 Mar;24(3):308.e5-308.e8.
    https://www.ncbi.nlm.nih.gov/pubmed/28811242
  • Dietz J, Susser S, Vermehren J, et al.: Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals. Gastroenterology 2018 Mar, 154:976–988.
    https://www.ncbi.nlm.nih.gov/pubmed/29146520
  • Harrington PR, Komatsu TE, Deming DJ, et al.: Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: Regulatory analyses and perspectives. Hepatology 2018 Jun, 67:2430–2448.
    https://www.ncbi.nlm.nih.gov/pubmed/29194682
  • Hezode C, Reau N, Svarovskaia ES, et al.: Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies. J Hepatol 2018 May, 68:895–903.
    https://www.ncbi.nlm.nih.gov/pubmed/29221887
  • Omar H, El Akel W, Elbaz T, et al.: Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt. AlimentPharmacolTher 2018 Feb, 47:421–431.
    https://www.ncbi.nlm.nih.gov/pubmed/29193226
  • Palanisamy N, Kalaghatgi P, Akaberi D, et al.: Worldwide prevalence of baseline resistance-associated polymorphisms and resistance mutations in HCV against current direct-acting antivirals. Antivir Ther 2018 May.
    https://www.ncbi.nlm.nih.gov/pubmed/29745936
  • Papatheodoridis GV, Hatzakis A, Cholongitas E, et al.: Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe. J Viral Hepat. 2018 Mar;25 Suppl 1:6-17.
    https://www.ncbi.nlm.nih.gov/pubmed/29508946
  • Petta S, Adinolfi LE, Fracanzani AL, et al.: Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. J Hepatol. 2018 Jul. pii: S0168-8278(18)30132-6.
    https://www.ncbi.nlm.nih.gov/pubmed/29505844
  • Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018 Jun;3(6):383-403.
    https://www.ncbi.nlm.nih.gov/pubmed/29599078
  • Puoti M, Foster GR, Wang S, et al.: High SVR12 with 8-week and 12-week Glecaprevir/Pibrentasvir: Integrated Analysis of HCV Genotype 1-6 Patients Without Cirrhosis. J Hepatol 2018 Mar
    https://www.ncbi.nlm.nih.gov/pubmed/29551706
  • Smith D, Magri A, Bonsall D, et al.: Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors. Hepatology 2018 Feb,
    https://www.ncbi.nlm.nih.gov/pubmed/29425396
  • Sorbo MC, Cento V, Di Maio VC, et al.: Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018. Drug Resist 2018 Mar, 37:17–39.
    https://www.ncbi.nlm.nih.gov/pubmed/29525636

2017

  • Bartlett SR, Grebely J, Eltahla AA, et al.: Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic review. Hepatol Commun. 2017 May 22;1(5):379-390.
    https://www.ncbi.nlm.nih.gov/pubmed/29404466
  • Cento V, Nguyen THT, Di Carlo D, et al.: Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens. PLoS One. 2017 May 18;12(5):e0177352.
    https://www.ncbi.nlm.nih.gov/pubmed/28545127
  • Cuypers L, Libin P, Schrooten Y, et al.: Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning. Infect Genet Evol. 2017 Sep;53:15-23.
    https://www.ncbi.nlm.nih.gov/pubmed/28499845
  • Cuypers L, Vrancken B, Fabeni L, et al.: Implications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy. BMC Evol Biol. 2017 Mar 7;17(1):70. https://www.ncbi.nlm.nih.gov/pubmed/28270091
  • d’Arminio Monforte A, Cozzi-Lepri A, Ceccherini-Silberstein F, et al.: Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort. PLoS One. 2017 May 17;12(5):e0177402.
    https://www.ncbi.nlm.nih.gov/pubmed/28520749
  • Karampatou A, Han X, Kondili LA, et al.: Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV. J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32259-6.
    https://www.ncbi.nlm.nih.gov/pubmed/28882581
  • Komatsu TE, Boyd S, Sherwat A, et al.: Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir. Gastroenterology 2017 Feb, 152:586–597.
    https://www.ncbi.nlm.nih.gov/pubmed/27773808
  • Kondili LA, Gaeta GB, Brunetto MR, et al.: Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. PLoS One. 2017 Oct 4;12(10):e0185728.
    https://www.ncbi.nlm.nih.gov/pubmed/28977040
  • Lembo T, Saffioti F, Chiofalo B, et al.: Low prevalence of hepatitis B and hepatitis C virus serum markers in a cohort of pregnant women from Southern Italy. Dig Liver Dis. 2017 Dec; 49(12):1368-1372.
    https://www.ncbi.nlm.nih.gov/pubmed/28818677
  • Lenci I, Bosa A, Milana M, et al.: Evidence of Spontaneous Post-transplant HCV Eradication in Two Failed DAA Treatments Awaiting Liver Transplantation. Dig Dis Sci. 2017 Aug;62(8):2193-2195. https://www.ncbi.nlm.nih.gov/pubmed/28500586
  • Maimone S, Caccamo G, Squadrito G, et al.:A combination of different diagnostic tools allows identification of inactive hepatitis B virus carriers at a single time point evaluation. Liver Int. 2017 Mar;37(3):362-368.
    https://www.ncbi.nlm.nih.gov/pubmed/27606573
  • Pellicelli AM, Pace Palitti V, Vignally P, et al.: Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study. Liver Int. 2017 May;37(5):653-661.
    https://www.ncbi.nlm.nih.gov/pubmed/27782373
  • Petta S, Marzioni M, Russo P, et al.: Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. Lancet Gastroenterol Hepatol. 2017 Jun;2(6):427-434.
    https://www.ncbi.nlm.nih.gov/pubmed/28497758
  • Puoti M, Lorenzini P, Cozzi-Lepri A, et al.: Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. Clin Microbiol Infect. 2017 Apr;23(4):267.e1-267.e4.
    https://www.ncbi.nlm.nih.gov/pubmed/27956268
  • Struble K, Chan-Tack K, Qi K, et al.: Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration’s evaluation. Hepatology 2017 Oct, 67:482–491.
    https://www.ncbi.nlm.nih.gov/pubmed/29059462
  • Welzel TM, Bhardwaj N, Hedskog C, et al.: Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses. J Hepatol 2017 Aug, 67:224–236.
    https://www.ncbi.nlm.nih.gov/pubmed/28343981

2016

  • Ceccherini Silberstein F, Di Maio VC, Aragri M, et al.: Hepatitis C virus gene sequencing as a tool for precise genotyping in the era of new direct antiviral agents. Hepatology. 2016 Mar;63(3):1058-9.
    https://www.ncbi.nlm.nih.gov/pubmed/25974082
  • Chen ZW, Li H, Ren H, et al.: Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data. SciRep 2016 Feb, 6:20310.
    https://www.ncbi.nlm.nih.gov/pubmed/26842909

2015

2014

  • Di Maio VC, Cento V, Mirabelli C, et al.: Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors. Antimicrob Agents Chemother. 2014 May;58(5):2781-97.
    https://www.ncbi.nlm.nih.gov/pubmed/24590484